- Dalton Pharma Services has installed its RoboFil™ aseptic powder fill-finish system at its Toronto, Canada facility.
- The automated isolator-based platform expands capacity and supports development through commercial GMP manufacturing.
Dalton Pharma Services has installed a RoboFil™ aseptic powder fill-finish system at its facility in Toronto, Canada, expanding its contract manufacturing capabilities for sterile drug product production.
The RoboFil™ platform is a fully automated, isolator-based system designed for aseptic powder fill-finish programs. It combines robotic handling with isolator technology to reduce operator intervention, which is identified as a primary contamination risk in aseptic operations. The system is intended to improve dose accuracy, process consistency, and sterility assurance.
The installation enables flexible manufacturing across different vial formats and supports rapid changeovers. According to the company, the platform can accommodate both early-stage development batches and repeatable GMP production campaigns, aligning with a range of clinical and commercial supply needs.
The system is described as Annex 1–aligned and is expected to enhance operational flexibility while increasing fill-finish capacity at the Toronto site. This addition supports Dalton Pharma Services’ broader offering in CDMO and contract manufacturing services.
“RoboFil™ reflects Dalton’s commitment to investing in advanced technologies that enable our clients to execute aseptic powder fill-finish with confidence.”
Dr. Jixing Wang, President of Dalton Pharma Services
